FDA accepts Synergy’s sNDA for Trulance to treat adults with IBS-C
The Prescription Drug User Fee Act (PDUFA) date is January 24, 2018. TRULANCE is a once-daily tablet approved by the FDA for the treatment of adults with chronic
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).
The project will use AbCellera’s single-cell screening platform to profile vaccine-specific human antibodies elicited by seasonal influenza vaccination and to generate large panels of human monoclonal antibodies with
The study dubbed APHINITY, compared Perjeta-based regimen with Herceptin and chemotherapy alone as an adjuvant therapy in 4,805 people with operable HER2-positive eBC. The Perjeta-based regimen is made up of
The new cognitive solution will use real-world data and advanced analytical techniques to better understand the anticipated outcomes of several breast cancer treatments. Novartis expertise in breast cancer, along with IBM